SCHEMBL6528320

SCHEMBL6528320

CNc1ccc2oc3ccc(NCc4cccc5ccccc45)cc3c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.44
IGF1R P08069 1/20 0.44
FLT4 P35916 1/20 0.44
KDR P35968 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
GFER P55789 1/20 0.42
ALDH1A1 P00352 3/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
F12 P00748 1/20 0.40
FYN P06241 1/20 0.40
SRC P12931 1/20 0.40
KDM4E B2RXH2 2/20 0.39
MAOB P27338 2/20 0.39
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CNR2 P34972 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481920 0.91 EGFR (0.50) EGFRIGF1RFLT4KDRMEN1
SCHEMBL6775761 0.86 EGFR (0.44) EGFRIGF1RFLT4KDRMEN1
SCHEMBL6768296 0.86 MAOB (0.45) EGFRIGF1RFLT4KDRMEN1
SCHEMBL6483960 0.84 MAOB (0.45) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL6484206 0.83 MAPT (0.52) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL7543908 0.82 NOX1 (0.39) EGFRIGF1RFLT4KDRMEN1
SCHEMBL6485086 0.81 LOXL2 (0.39) EGFRIGF1RFLT4KDRMEN1
SCHEMBL6775567 0.81 KMT2A (0.44) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL6482769 0.81 MAOB (0.41) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL6483263 0.80 LRRK2 (0.41) KMT2AALDH1A1MAPTKDM4EMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 EGFR 1980/4885IGF1R 3806/4885FLT4 3706/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 EGFR 1272/4885IGF1R 2250/4885FLT4 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.